Any woman who has a scale t -2.

In-Depth from Adam antirezorbtivnoy funds. Antiresorptives include bisphosphonates, hormone therapy, selective estrogen receptor modulators, (SERMs), and calcitonin. Bisphosphonates standard drugs used to treat osteoporosis. These drugs block resorption (preventing bone break), which slows the rate of bone tissue, but they can not restore bone. Because resorption and reformation occur naturally as a continuous process, blocking resorption may eventually also reduce bone formation. Anabolic (bone forming) Drugs. Drugs to restore bone, known as anabolics. The main anabolic drug low dose parathyroid hormone (PTH), which is introduced by injection. This medicine can help restore bone and prevent fractures. PTH is relatively new and long-term effects are still unknown. Fluoride is another bone building drugs, but it has its limitations and is not used. Both types of drugs are effective in preventing bone loss and fractures, although they can cause different types of side effects. Bisphosphonates are the main agents for the prevention and treatment of osteoporosis. They can help reduce risk and spine and hip fractures, including patients with breaks to bones. Studies show that these drugs are effective and safe, at least 10 years. Finally, bone loss continues bisphosphonates. This may be due to the fact that bone breakdown is one of the two phases in a continuous process of restoration of bone tissue. Over time, blocking resorption interrupts this process and reduces the second half of the process - the formation of bone. Some, but not all patients with low risk of fractures may stop using the drug after 5 years. Other patients should continue to receive this type of drug on a regular basis. Candidates. National Osteoporosis Foundation guide recommended the following people should take or consider taking bisphosphonates:

Any woman who has a scale T -2. 5 or below on DXA scanning

Women who have a scale T -1 to -2. 5 (indicating low bone density [osteopenia]) and the presence of fractures in the history of brands.

Bisphosphonates for osteoporosis prevention and treatment are available in various forms:

Oral bisphosphonates. These tablets contain alendronate (fosamaks, total) ryzedronat (Actonel), and ibandronat (Boniva). Alendronate and ryzedronat taken once a week. Ibandronat available as once a month pill. Ryzedronat also available once a month pills and tablets that contain calcium. Alendronate is available in a formulation that vitamin D. ryzedronat and alendronate are approved for men and women. Injectable bisphosphonates. Zoledronovoyi acid (Reclast), is designed to treat and prevent osteoporosis in postmenopausal women. It is given as a once a year injection. Injectable forms ibandronat (Boniva) requires injections 4 times a year. Injectable bisphosphonates are an alternative for patients who may have difficulty swallowing pills or sitting after oral administration of bisphosphonates. Side effects. Saddest side effects of bisphosphonates are gastrointestinal problems, including cramps in the stomach and heartburn. These symptoms are very common and occur in almost half of all patients. Other side effects may include irritation of the esophagus (tube that connects the mouth to the stomach) and ulcers of the esophagus or stomach. Some patients may have muscle and joint pain. To avoid problems with the stomach, doctors recommend:

Take tablets on an empty stomach in the morning from 6 - 8 ounces of water (not juice or soda or mineral water). After the pill remains in an upright position. Do lasix water pill not eat or drink for 30 - 60 minutes. (Check your medication dosing instructions for exact time).

If you develop chest pain, heartburn or difficulty swallowing, stop taking the drug and seek medical advice. Other Issues. Osteonecrosis (bone death) of the jaw is a rare side effect that occurred mainly in patients who received intravenous bisphosphonates for cancer treatment (not osteoporosis). Many of these patients had severe dental procedures before developing osteonecrosis. However, this bone decay condition also reported in some patients taking bisphosphonates by mouth (mainly alendronate). Symptoms can include pain or swelling of the jaw, gum infections and poor healing of gums. Talk to your doctor or dentist if you have any jaw or gum discomfort while taking bisphosphonates drugs. There was also concern that bisphosphonates may increase the risk of atrial fibrillation, cardiac arrhythmia is common in elderly patients. FDA monitors reports of atrial fibrillation in patients using bisphosphonates, but this is not recommended to change the practice setting. At the end of 2008, the FDA evaluated almost 20,000 patients who received bisphosphonates without giving a clear link between these drugs and risk of atrial fibrillation. Raloksifen (Evista) belongs to a class of drugs called selective estrogen receptor modulators, (SERMs). These drugs are similar but not identical, to estrogen. Raloksifen provides bone benefits of estrogen without increasing the risk for estrogen-related breast and uterine cancer. Raloksifen was approved in 1997 for the prevention of osteoporosis in postmenopausal women, and in 1999 for the treatment of osteoporosis in postmenopausal women. In 2007, the Food and Drug Administration approved raloksifen to prevent breast cancer in postmenopausal women suffering from osteoporosis and in postmenopausal women at high risk of invasive breast cancer. Although there are many drugs SERM, raloksifen is the only approved to treat and prevent osteoporosis. Only in postmenopausal women with or at risk of osteoporosis should take this drug. Studies show that raloksifen can stop thinning bones and help build the best quality and strong bones. Side effects. Raloksifen increases the risk of blood clots in the veins. In connection with this side effect, raloksifen also increases the risk of stroke (but not other types of cardiovascular disease). These side effects, though rare, very serious. Women should not take this drug if they have a history of blood clots, or if they have certain risk factors for stroke and heart disease. Most mild side effects include hot flashes and leg cramps. Prepared by the thyroid gland, natural calcitonin regulates calcium levels by suppressing the activity of osteoclasts, bone destruction. The drug version is derived from salmon and is available as a nasal spray (Miacalcin) and enter form (Calcimar). Calcitonin is used to prevent osteoporosis. This refers to osteoporosis. This can be effective for spinal protection (but not hip) in men and women. Calcitonin may be an alternative for patients who can not take bisphosphonates or SERM. It seems also to relieve bone pain associated with established osteoporosis and fractures. Side effects. Side effects include headache, dizziness, anorexia, diarrhea, skin rash and swelling (edema). The most common side effect experienced with injections of nausea, with or without vomiting. This is less nasal spray. Nasal spray may cause nosebleeds, sinusitis, inflammation of the membranes of the nose. In addition, many people who take calcitonin develop resistance or allergic reactions after prolonged use. Teriparatide (Forteo), intravenous drug users with selected amino acids found in parathyroid hormone, may help reduce the risk for spine and without fractures of the spine. Despite the high level of continuous parathyroid hormone (PTH) can cause osteoporosis, daily injections of small and intermittent doses of this hormone actually stimulates bone production and increase bone mineral density. Teriparatide is usually recommended for patients with osteoporosis who are at high risk of fractures. Side effects of PTH are generally mild and include nausea, dizziness and leg cramps. No significant complications have been reported so far. Nasal spray version of PTH is currently in clinical trials. Early animal studies reported bone tumors in mice that were given parathyroid long-term. This effect is not observed in humans so far. However, people with Paget's disease (a disease in which bones thicken, but also weakens), should not take parathyroid hormone, because they are at higher than normal risk of bone tumors. Hormone replacement therapy (HRT) was previously used to prevent osteoporosis, but rarely used for these purposes today. Studies have shown that estrogen increases the risk of breast cancer, blood clots, strokes and heart attacks. For this reason, women need to balance the benefits that HRT has on bone loss, with the risks it carries for other serious diseases. FDA recommends that women first try other drugs to prevent osteoporosis. Biological drugs. Denosumab (Prolia) is a monoclonal antibody drug that is given once every 6 months by injection. In August 2009, FDA advisory panel recommends approval of the drug for the treatment of postmenopausal women suffering from osteoporosis and treatment of osteoporosis in men with prostate cancer. The Committee voted against approval of denosumab to treat osteoporosis and prevent bone loss. There are fears that the safety of denosumab may increase the risk of skin infections. New SERMs. Bazedoxifene (Viviant) and lasofoxifene (Fablyn) two new selective estrogen receptor modulators (SERMs), which is being considered for approval by FDA. FDA weighs the potential benefits of these drugs against their risks, including stroke. If FDA approval may limit these drugs to certain groups of women such as those at much higher risk of fractures. .